XNAS · Healthcare · Biotechnology
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.68 | -0.95 | -39.71% | $0 | ❌ Miss | -3.55% | +0.00% | — |
| 2026-03-10 | Q4 2025 | -1.27 | -6.73 | -429.92% | $0 | ❌ Miss | +0.68% | -0.82% | -21.75% |
| 2025-11-12 |
| Q3 2025 |
| -1.19 |
| -2.91 |
| -144.54% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
Showing last 3 quarters.